The FDA's Center for Veterinary Medicine (CVM) has launched a pilot program with a bold mission: to bolster domestic manufacturing of animal drugs and their active ingredients. This initiative is a strategic move to ensure a resilient veterinary pharmaceutical supply chain, prevent shortages, and support the broader goal of increasing American pharmaceutical manufacturing. By prioritizing applications for animal drugs with both finished products and active ingredients made in the US, the CVM is taking a proactive approach to address a critical vulnerability in the veterinary pharmaceutical supply chain. This vulnerability arises from the significant reliance on active ingredients and finished products manufactured outside the US, which can leave the supply of animal drugs susceptible to disruptions. The program offers two key incentives for eligible sponsors: priority review consideration for complete Chemistry, Manufacturing and Controls (CMC) technical sections, and the ability to include a second domestic source of active ingredient in the original submission, eliminating the need for post-approval supplemental applications. This approach provides manufacturers with more flexibility and helps safeguard supply continuity. The pilot program is modeled on successful human-drug efforts, such as the ANDA Prioritization Pilot, and is part of a wider set of actions to support and strengthen domestic drug manufacturing. The CVM plans to monitor the program's effectiveness and may make adjustments based on stakeholder feedback. This initiative is a significant step towards a more secure and sustainable veterinary pharmaceutical supply chain, and it highlights the FDA's commitment to ensuring the availability and reliability of animal drugs for the American market.
